NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.

NVB Europe has developed the Aptamarker platform, a novel approach to High-Plex proteomics that involves the application of 268 million probes to every sample. This depth enables the characterization of all proteins present in a sample to identify biomarkers for medical states or outcomes such as presence or stage of a disease, prediction of relapse versus remission, stratification of patients who respond to treatment, and characterization of predisposition to negative side-effects.

The application of our deep dataset to these predictions is predicated on the use of AI.

Together with NVIDIA capacity we will be able to expand the modelling of probe/protein interactions on a tertiary structural level. The capacity to visualize and quantify these interactions moves our power beyond characterization of proteins as biomarkers to regions within the proteins (epitopes) as biomarkers.

We are excited that with the support of the NVIDIA Inception program and our existing use of NVIDIA cloud we will be able to achieve a transformative leap forward in the understanding of the basis of disease and treatment. We will accelerate the development of improved treatments and provide a real basis for the delivery of personalized medicine.